The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery
Open accessAbstract
BACKGROUND: Growing evidence suggests that immunotherapy and radiation therapy can be synergistic in the treatment of cancer. This study was performed to determine the effect of the relative timing and type of immune checkpoint therapy on the response of melanoma brain metastases (BrMets) to treatment with stereotactic radiosurgery (SRS). METHODS: Seventy‐five melanoma patients with 566 BrMets were treated with both SRS and immune checkpoint therapy between 2007 and 2015 at a single institution. Immunotherapy and radiosurgery treatment of any single lesion were considered concurrent if SRS was administered within 4 weeks of immunotherapy. The impact of the timing and type of immunotherapy on the lesional response was determined with the Wilcoxon rank‐sum test, which was used to compare the median percent lesion volume change 1.5, 3, and 6 months after SRS treatment, with significance determined by P = .0167 according to the Bonferroni correction for multiple comparisons. RESULTS: Concurrent use of immunotherapy and SRS resulted in a significantly greater median percent reduction in the lesion volume at 1.5 (−63.1% vs −43.2%, P < .0001), 3 (−83.0% vs −52.8%, P < .0001), and 6 months (−94.9% vs −66.2%, P < .0001) in comparison with nonconcurrent therapy. The median percent reduction in the lesion volume was also significantly greater for anti–programmed cell death protein 1 (anti–PD‐1) than anti–cytotoxic T‐lymphocyte‐associated protein 4 (anti–CTLA‐4) at 1.5 (−71.1% vs −48.2%, P < .0001), 3 (−89.3% vs −66.2%, P < .0001), and 6 months (−95.1% vs −75.9%, P = .0004). CONCLUSIONS: The administration of immunotherapy within 4 weeks of SRS results in an improved lesional response of melanoma BrMets in comparison with treatment separated by longer than 4 weeks. Anti–PD‐1 therapy also results in a greater lesional response than anti–CTLA‐4 after SRS. Cancer 2016;122:3051‐3058. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Cited by
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 374
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
Metadata
- Authors
- Qian, J. M., Yu, J. B., Kluger, H. M., & Chiang, V. L. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-06-10
- Volume
- 122
- Issue
- 19
- Pages
- 3051-3058
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2415633845
- Cited by
- 212
- References
- 2
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.